Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account. Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/turdcapital
Steven Jon Kaplan began TrueContrarian.com in August 1996 as a weekly blog and later expanded this to a daily newsletter with intraday updates in February 2006. Steve provides financial consulting which emphasizes long-term tax and investment planning. He has been trading his own account, and those of family and close friends, since 1981, and handles separately managed accounts for qualified clients. As a registered investment advisor, Steve charges a 20% performance fee on net profits and zero management fees. He has been quoted in Barron's, Market Watch, Dow Jones Newswires, Seeking Alpha, and Kitco. Steve has appeared on Market Watch cable TV with Stacey Delo and was interviewed by Alisa Parenti on Bloomberg. Since 2010, Danielle Kerani Oberdier has served as Steve's business associate.
Steve enjoys running with the New York Road Runners, composing and performing on piano and voice, writing stories, and traveling to unique places. He enjoys hearing from anyone about a wide range of topics, so please let him know what you think about the web site or whatever is on your mind. You can find his music at http://www.reverbnation.com/stevenjonkaplan .
With more than 30 years experience as a research synthetic organic and medicinal chemist, Dr. Marlowe earned a set of bachelor degrees in organic chemistry and biological sciences from the University of California, Irvine working with Professor Larry E. Overman (multiple Arthur C. Cope award winner). Gaining a PhD in organic chemistry from the University of California, Berkeley with Professor Emeritus Paul A. Bartlett (NIH MERIT award, Humboldt Senior Scientist Award, Cope Scholar Award) in the field of bioorganic chemistry, he then attended Stanford University as an NIH post-doctoral fellow under a NIS award winner Professor Emeritus William S. Johnson in synthetic organic chemistry. Dr. Marlowe has worked in a number of fields including agricultural chemistry with Dow Chemical, biotechnology with Chiron Corporation (now Novartis Pharmaceuticals), and in medicinal chemistry with COR Therapeutics Inc. (acquired by Millennium Pharmaceuticals). He is presently working for the biopharmaceutical company Exelixis Inc. of South San Francisco. He has been responsible for the discovery and advancement of many drug candidates into the market place, NDA (New Drug Application) stage, human clinical testing phase and IND (Investigational New Drug) stage. He has authored over 30 publications in leading journals and is holder of over 25 world and US patents.